Clinical trials: Shortness of Breath
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
The primary objective of the study is to investigate the effect of the combined therapy 18 μg tiotropium q.d. plus pulmonary rehabilitation versus placebo plus pulmonary rehabilitation on 6-minute walking distance (6MWD) after 7…
- Trial name
- NCT02172508
- Testing
- Tiotropium Inhalation Capsule
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Asthma
Prevalence and Reversibility of Lung Hyperinflation in Asthma
The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.
- Trial name
- Dist'air2 (NCT01573364)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Open-label comparative multicentric cohort study in COPD patients with LABA/ICS, switched to either tiotropium/olodaterol and observed for 12 weeks approximately.
- Trial name
- NCT03954132
- Testing
- Spiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)
- Where
- 75 sites in Germany
- Volunteers
- 469 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety Study in Adolescent and Adult Patients With Asthma
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.
- Trial name
- NCT01476904
- Testing
- Primatene Mist, Epinephrine inhalation
- Where
- 27 sites in United States
- Volunteers
- 208 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Shortness of Breath
A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation
The purpose of this study is to assess the efficacy of Caption LungAI.
- Trial name
- NCT05992324
- Testing
- Caption LungAI
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- Caption Health, Inc.
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
To determine if ABX-IL8 will improve shortness of breath.
- Trial name
- NCT00035828
- Testing
- ABX-IL8
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Abgenix
Congestive Heart Failure, Cardiomyopathy
FAST (Fluid Accumulation Status Trial)
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Conditions
- Congestive Heart Failure, Cardiomyopathy, Dyspnea, Pulmonary Edema
- Trial name
- NCT00289276
- Testing
- Fluid Status Monitoring (OptiVol™)
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 156 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable…
- Conditions
- Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
- Trial name
- Assert-IQ (NCT06172699)
- Testing
- Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- Abbott Medical Devices
Longitudinal Observational Study With 6 Months Follow-up
Longitudinal Observational Study for mIddle Term Follow-up Patients Admitted for Acute Dyspnea in TunIsia
The purpose of the SIDI study is to follow, few months after discharge from the hospital, the patients admitted to the 3 emergency departments in Tunisia for acute dyspnea and to determine the proportion and the factors favoring…
- Trial name
- SIDI (NCT04947358)
- Where
- Tunisia
- Volunteers
- 180 people
- Sponsor
- S Form Pharma
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Heart Failure, Dyspnea
Correlation Research Study: IQ2, NcIQ and IQ101
The new NcIQ thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but also include second radio frequency signal to permit the…
- Conditions
- Heart Failure, Dyspnea, Hypertension, Pacemaker
- Trial name
- NMT-CT (NCT00491777)
- Testing
- Noninvasive Hemodynamic Patient Monitor
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Noninvasive Medical Technologies, Inc.
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- VESPER-OSA 2 (NCT07881757)
- Testing
- Berobenatide
- Where
- 2 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Heart Failure, Congestive, Dyspnea
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic…
- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Trial name
- NCT00043836
- Testing
- ALT-711
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Synvista Therapeutics, Inc
Shortness of Breath, Heart Failure
Biomarkers in Acute Heart Failure
Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency…
- Trial name
- BACH (NCT00537628)
- Where
- 15 sites in United States, Germany and 6 more
- Volunteers
- 1,641 people
- Sponsor
- Brahms AG
Dyspnea, Hypercapnia
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Device Equivalence
This study will evaluate the ability of a new High Velocity Nasal Insufflation [HVNI] device design to effect ventilation and related physiological responses relative to the current HVNI device design.
- Conditions
- Dyspnea, Hypercapnia, Respiratory Insufficiency
- Trial name
- NCT04590014
- Testing
- Conventional Precision Flow, HVNI HVT2.0 Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Vapotherm, Inc.